A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma. (Q36671874)
Jump to navigation
Jump to search
scientific article published on 29 January 2013
Language | Label | Description | Also known as |
---|---|---|---|
English | A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma. |
scientific article published on 29 January 2013 |
Statements
A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma (English)
A H Strickland
M Lichinitser
A V S Suresh
G Manikhas
J Shapiro
W Rogowski
X Huang
B Wu
D Warner
R Jain
29 January 2013
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference